Category Archives: Global News Feed

PRINCETON, N.J., April 28, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced preliminary expectations for first quarter 2023 Twirla® demand, net revenue and operating expenses.

Read more from the original source:
Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023

NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended March 31, 2023, on Monday, May 8, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Tuesday, May 9, 2023, at 9:00 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and Interim CEO; Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commerical Officer and Vignesh Rajah, Chief Medical Officer.

Go here to read the rest:
Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023

PALO ALTO, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that Henry Ji, Ph.D., Executive Chairman of Scilex, and Jaisim Shah, Chief Executive Officer and President of Scilex will participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq:

Visit link:
Scilex Holding Company to Participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq on May 2, 2023

Company announcement – No. 18 / 2023

Continued here:
Total number of shares and voting rights in Zealand Pharma at April 28, 2023

Liege, Belgium, 28 April 2023 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of transparency from Alychlo NV, with registered offices at Lembergsesteenweg 19. 9820 Merelbeke, on 25, April 2023.

See the original post here:
Publication of a transparency notification received from Alychlo NV

PRESS RELEASE

More:
AB Science reports its revenues for the year 2022 and provides an update on its activities

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

Here is the original post:
ObsEva Annual Report 2022

ISTANBUL, Turkey, April 28, 2023 (GLOBE NEWSWIRE) -- Protect Pharmaceutical Corp.‘s (OTC: PRTT) (“Company”) President Ali Yildiz addresses the Company’s shareholders with a corporate update on expansion and forward-looking progress.

Read more here:
Protect Pharmaceutical Corp.‘s (PRTT) President Ali Yildiz Provides its Shareholders with a Corporate Update

AUSTIN, Texas, April 28, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company’s Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-15. The reverse stock split will become effective at 12:01 a.m. Eastern Time on May 1, 2023, and the Company’s common stock will open for trading on The Nasdaq Capital Market on a post-split basis on May 1, 2023 under the Company’s existing trading symbol, “PSTV.” At such time, the Company’s common stock will also commence trading with a new CUSIP number, 72941H509.

Continue reading here:
Plus Therapeutics Announces Reverse Stock Split

Regulated Information - Denominator

Continue reading here:
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS